The discovery partnership spans for an initial period of 3 years, under which Norgine will be provided with a platform to develop multiple targets utilising Jubilant’s integrated drug discovery platform targeting gastrointestinal diseases.
As per the agreement, Jubilant should deliver preclinical candidates to Norgine who will own all rights to further develop and commercialize the candidates.
Jubilant Global Drug Discovery and Development president and CEO Sri Mosur said they are confident their platform will enable Norgine’s quest for novel and optimal therapies in delivering affordable care to the unmet needs of patients in Europe and in the area of gastrointestinal disease.